Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
IBI3033 in moderate-to-severe atopic dermatitis
NCT07549984Phase 1Not yet recruiting
- Sponsor
- Innovent Biologics
- Start
- Apr 2026
- Primary completion
- Feb 2027
- Modality
- Peptides
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of IBI3033 in atopic dermatitis (AD) (3 arms), sponsored by Innovent Biologics. Primary endpoint: Incidence of adverse events and serious adverse events at 16 weeks. Planned start Apr 2026; status: not yet recruiting.
02
Drugs
IBI3033
03
Conditions
atopic dermatitis (AD)
Beyond the preview
Go deeper on NCT07549984.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07549984.